CYCN
Cyclerion Therapeutics Inc
NASDAQ: CYCN · HEALTHCARE · BIOTECHNOLOGY
$3.31
-0.30% today
Updated 2026-04-30
Market cap
$12.73M
P/E ratio
—
P/S ratio
6.14x
EPS (TTM)
$-1.11
Dividend yield
—
52W range
$1 – $8
Volume
5.6M
WallStSmart proprietary scores
21
out of 100
Grade: F
Strong Sell
Investment rating
5.3
Growth
C+5.0
Quality
C+2.0
Profitability
F6.7
Valuation
B—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$8.00
+141.69%
12-Month target
—
—
Intrinsic (DCF)
$5.04
Margin of safety
+75.79%
Price chart
X-Ray snapshot
Strengths
+ 75.79% below intrinsic value
Risks
- Thin margins at -170.10%
- Negative free cash flow $-1.58M
- Revenue declining -43.20% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $297000.00 | $0.00 | $2.00M | $2.07M | $2.07M |
| Net income | $-44.08M | $-5.26M | $-3.06M | $-3.53M | $-799000.00 |
| EPS | — | — | — | — | $-1.11 |
| Free cash flow | $-40.61M | $-21.25M | $-4.33M | $-3.31M | $-1.58M |
| Profit margin | -14,841.08% | — | -152.85% | -170.11% | -170.10% |
Peer comparison
Smart narrative
Cyclerion Therapeutics Inc trades at $3.31. Our Smart Value Score of 21/100 indicates the stock is weak. TTM revenue stands at $2.07M. with profit margins at -170.10%. Our DCF model estimates intrinsic value at $5.04.
Frequently asked questions
What is Cyclerion Therapeutics Inc's stock price?
Cyclerion Therapeutics Inc (CYCN) trades at $3.31.
Is Cyclerion Therapeutics Inc overvalued?
Smart Value Score 21/100 (Grade F, Strong Sell). DCF value $5.04.
What is the price target of Cyclerion Therapeutics Inc (CYCN)?
The analyst target price is $8.00, representing +141.7% upside from the current price of $3.31.
What is the intrinsic value of Cyclerion Therapeutics Inc (CYCN)?
Based on our DCF model, intrinsic value is $5.04, a +75.8% margin of safety versus $3.31.
What is Cyclerion Therapeutics Inc's revenue?
TTM revenue is $2.07M.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio6.14x
ROE-39.30%
Beta0.89
50D MA$2.12
200D MA$2.07
Shares out0.00B
Float0.00B
Short ratio—
Avg volume5.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—